Retrospective Case Series Highlighting the Real-World Experience of Nirogacestat Therapy in Young Adults With Desmoid Tumors
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jul 2026 · 1 min read
In brief
In brief
This retrospective case series reports real-world outcomes of nirogacestat therapy in 11 young adult patients with desmoid tumors over 14 months. Results showed 88% achieved tumor volume reduction, 90% experienced rapid pain improvement, with manageable toxicities including diarrhea and ovarian dysfunction in this FDA-approved gamma secretase inhibitor treatment.
Written by the GCMD Library team from the article.
Statements in this article
Desmoid tumors have a peak incidence in young adulthood and often cause pain, loss of function, and diminished quality of life.
Nirogacestat, a selective gamma secretase inhibitor, was approved by the US Food and Drug Administration in November 2023 for the treatment of patients with desmoid tumors based on findings from the Phase III DeFi trial.
The median patient age in this series was 26 years.
The median duration of nirogacestat therapy at the time of the study was 8 months.
RECIST responses included one patient with a partial response, eight with stable disease, and two were deemed radiologically inevaluable.
Eight out of nine evaluable patients (88%) demonstrated a reduction in tumor volume and improvement in MRI T2-weighted signal intensity.
Nine out of 10 patients who presented with pain (90%) reported rapid improvement.
The most common toxicities of nirogacestat included diarrhea, nausea, rash, and ovarian dysfunction.
Discontinuation of nirogacestat was necessary in one patient due to severe diarrhea.